

Epitomes

Important Advances in Clinical Medicine

General and Family Practice

The Scientific Board of the California Medical Association presents the following inventory of items of progress in general and family practice. Each item, in the judgment of a panel of knowledgeable physicians, has recently become reasonably firmly established, both as to scientific fact and important clinical significance. The items are presented in simple epitome and an authoritative reference, both to the item itself and to the subject as a whole, is generally given for those who may be unfamiliar with a particular item. The purpose is to assist busy practitioners, students, research workers or scholars to stay abreast of these items of progress in general and family practice that have recently achieved a substantial degree of authoritative acceptance, whether in their own field of special interest or another.

The items of progress listed below were selected by the Advisory Panel to the Section on General and Family Practice of the California Medical Association and the summaries were prepared under its direction.

Reprint requests to Division of Scientific and Educational Activities,
California Medical Association, 44 Gough Street, San Francisco, CA 94103

***Chlamydia trachomatis* Infections**

DURING THE past decade, the importance of *Chlamydia trachomatis* as a human pathogen has become increasingly apparent. Although lacking the notoriety of *Neisseria gonorrhoeae*, *C trachomatis* is known to produce a similar spectrum of human illness and is now considered a major sexually transmitted pathogen in the United States. In fact, studies indicate that we are currently in the midst of a "*Chlamydia* epidemic."

Chlamydia trachomatis is an obligate, intracellular parasite that has been implicated in a wide spectrum of human infections. Genital chlamydial infections occurring in men include nongonococcal urethritis, epididymitis, lymphogranuloma venereum, proctitis and possibly Reiter's syndrome. In women *C trachomatis* has been implicated as a cause of pelvic inflammatory disease, acute urethral syndrome, mucopurulent cervicitis, Bartholinitis, lymphogranuloma venereum, postpartum endometritis and perihepatitis (Fitz-Hugh-Curtis syndrome). Neonatal infections caused by *Chlamydia* include inclusion conjunctivitis and afebrile pneumonia. Finally, the leading cause of preventable blindness in the world, trachoma, is also due to this microorganism.

The most sensitive method of diagnosis remains the tissue-culture isolation of *C trachomatis*. This test, though, is generally available only in laboratories of referral hospitals or large public health departments. Direct cytologic techniques for identifying *Chlamydia*-infected cells lack the sensitivity required for clinical use. Serologic tests are generally not useful in diagnosing current chlamydial genital infections due to a high prevalence of antibody from previous infections; they are of value in diagnosing neonatal chlamydial pneu-

monia and lymphogranuloma venereum.

As a result of the lack of a convenient, accurate test for diagnosing *C trachomatis*, decisions regarding diagnosis or treatment are frequently made on the basis of the clinical features, the exclusion of other possible pathogens such as gonorrhea and tracing contacts of patients who have nongonococcal urethritis, nongonococcal pelvic inflammatory disease and mucopurulent cervicitis. In view of the estimate that from 10% to 20% of men and 40% of women with gonorrhea are coinfecting with *Chlamydia*, consideration should be given to empirically treating these patients with an antibiotic regimen effective against *C trachomatis*. Effective regimens against *Chlamydia* include seven-day courses of tetracycline, 500 mg four times a day, doxycycline, 100 mg twice a day, and erythromycin, 500 mg four times a day.

MARTIN QUAN, MD

REFERENCES

- Guze PA, Bayer AS, Anthony BF, et al: Spectrum of human chlamydial infections—Teaching Conference, Harbor-UCLA Medical Center, Torrance (Specialty Conference). *West J Med* 1981 Sep; 135:208-225
Holmes KK: The chlamydia epidemic. *JAMA* 1981 May 1; 245:1718-1723
Schachter J: Chlamydial infections (three parts). *N Engl J Med* 1978 Feb 23-Mar 9; 298:428-435; 490-495; 540-549

Human Insulin

OUR ABILITY to artificially synthesize the amino acid sequence of human insulin was first achieved in 1963. Due to the low yield and the impurity of the product, human insulin has not been synthesized by this method. Porcine and bovine insulins have been the mainstays of diabetic insulin therapy. A newly developed method of human insulin synthesis has led to licensure and marketing of this product for widespread clinical use.

By artificially splicing the plasmid specifying production of human insulin, *Escherichia coli* can become human insulin "factories." This is one of the first practical applications of recombinant DNA technology. Insulin produced by this method has been immunologically, chemically and physically identical to insulin produced by humans. This recombinant DNA human insulin shows no traces of *E coli* contamination nor of any other side products such as proinsulin.

The major theoretic advantage of human insulin is the diminishment or avoidance of antigenic reactions, both local and systemic. Although less common, the more serious systemic insulin reactions have been associated with clinical situations in which insulin usage has been intermittent and there was a known allergy to other materials such as penicillin. Human insulin (recombinant DNA) is not a panacea and can be antigenic when administered subcutaneously. Nevertheless, this new product should be useful in certain clinical situations.

Family physicians will encounter the need for the intermittent use of insulin in gestational diabetes and during physiologically stressful periods (such as in surgery and the intensive care unit) in cases of type II diabetes. Human insulin may be the first choice in these situations. Cases of newly diagnosed insulin-dependent diabetes may benefit from the use of human insulin, particularly if they have a strong history of multiple allergies. The incidence of lipoatrophy may be diminished. Costs for one vial of insulin at one pharmacy in metropolitan Los Angeles were as follows: human insulin, \$18; purified porcine insulin, \$11; bovine or porcine insulin, \$8. In a recent review, no evidence was found to support the use of human insulin in patients currently using older insulin preparations without allergic reactions.

WM. MacMILLAN RODNEY, MD

REFERENCES

- Grammer LC, Metzger BE, Patterson R: Cutaneous allergy to human (recombinant DNA) insulin. *JAMA* 1984 Mar 16; 251:1459-1460
Human insulin. *Med Lett Drugs Ther* 1983 Jun 24; 25:63-64
Skyler JS: Human insulin of recombinant DNA origin: Clinical potential. *Diabetes Care* 1982 Nov-Dec; 5(suppl 2):181-186

Cost-Effectiveness of Antenatal Rh Factor Immunoprophylaxis

REDUCING THE SEVERITY of Rh factor immunization, once it has occurred, is difficult. More effective by far is preventing the development of Rh factor immunization by administering Rh immune globulin. First licensed for clinical use in North America in 1968, Rh immune globulin injection will probably always prevent Rh factor immunization if given in an adequate dose before Rh factor immunization has taken place. The standard dose for prophylaxis is 300 μ g. Smaller doses have been almost as effective. In England and Australia, for example, the doses are 100 μ g and 125 μ g, respectively. However, 300 μ g of Rh immune globulin will protect a greater number of the women who occasionally have large transplacental hemorrhages.

In 1981 the American College of Obstetricians and Gynecologists reviewed protocols directed at further

decreasing the frequency of Rh factor immunization by the use of Rh immune globulin in the following cases: prophylactically during the antepartum period; after amniocentesis; after antepartum hemorrhage and fetal death; after postpartum and postabortional sterilization; after transfusion of platelet concentrates and granulocytes, and in an Rh-negative, unimmunized woman (whether D⁺ positive or D⁺ negative) after delivery of an Rh-positive or D⁺-positive infant. The most frequent reason for apparent postpartum failure of prophylaxis is most likely Rh factor immunization during pregnancy.

The cost-effectiveness of antepartum prophylaxis remains to be established. Treatment with Rh immune globulin at delivery only is very cost-effective. However, the addition of antenatal treatment where postpartum treatment is already routine is much less cost-effective. Furthermore, it is less cost-effective to limit treatment to women with homozygous Rh-positive husbands than to treat all women or all those with Rh-positive husbands. The possible savings by not treating women with Rh-negative fetuses is outweighed by the added costs of blood typing. Critics have also cited the increased requirements for Rh immune globulin, which may put hyperimmune Rh plasma donors at increased risk, as another disadvantage of antenatal prophylaxis.

There has already been considerable progress in reducing the incidence of Rh immunization. Routine antenatal Rh factor immunoprophylaxis is effective in further decreasing the rate of Rh factor isoimmunization by pregnancy, but greatly increases the demand for Rh immune globulin. It is appropriately done where Rh immune globulin supplies are adequate for all other needs, and cases of erythroblastosis fetalis still occur that might have been prevented by antenatal treatment. If antepartum prophylaxis is used, current recommendations are for the administration of 300 μ g of Rh immune globulin at 28 weeks' gestation in an unimmunized, Rh-negative woman. Another 300- μ g dose should be given after delivery of an Rh-positive or D⁺-positive baby.

KLEA D. BERTAKIS, MD, MPH

REFERENCES

- Bowman JM: Suppression of Rh isoimmunization—A review. *Obstet Gynecol* 1978 Oct; 52:385-393
Davey MG, Zipursky A: McMaster conference on prevention of Rh immunization. *Vox Sang* 1979; 36(1):50-64
Nusbacher J, Bove JR: Rh immunoprophylaxis: Is antepartum therapy desirable? *N Engl J Med* 1980 Oct 16; 303:935-937
The Selective Use of Rho(D) Immune Globulin (RhIG), technical bulletin #61. Washington, DC, American College of Obstetricians and Gynecologists, March 1981

Preventing Advanced Colorectal Cancer—Fecal Occult Blood Testing

RECENTLY THE American Cancer Society has initiated a three-year educational effort to change the way physicians and the public view the disease of colorectal cancer. The Colorectal Health Check (CHEC) Program will emphasize the expanded use of three standard diagnostic techniques for the early detection of colorectal carcinoma in asymptomatic patients. These tech-